Compounds / Metabolic / Bioglutide

Bioglutide

Bioglutide (NA-931 — Quadruple GLP-1/GIP/IGF-1/Glucagon Agonist)
MetabolicFDA: Not approved; preclinical/early research

Overview

Very early research. Quadruple agonism hypothesis: adding IGF-1R to triple agonism for muscle preservation during weight loss. Limited published data.

Mechanism of Action

Quadruple agonist — GLP-1R + GIPR + IGF-1R + glucagon receptor. Experimental compound exploring whether four-way agonism offers superior metabolic outcomes. Early research stage.

Pharmacokinetics

Half-life
16 hrs
Peak (Tmax)
2 hrs
Cleared
3.3 days

Molecular Profile

Type
Cyclic IGF-1 fragment derivative

Key Research Findings

Quadruple agonism; muscle preservation hypothesis; very early research stage.

Related Metabolic Compounds

SemaglutideTirzepatideRetatrutideCagrilintideMazdutideAOD-9604
Clinical Guidance

Research data is not a treatment plan. If you are considering Bioglutide, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Bioglutide? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals